Made on
Tilda
Deep brain stimulation is one of the few treatments that can substantially reduce severe, medication-refractory tremor in selected people with multiple sclerosis. However, outcomes in MS are considerably less predictable than in classic essential tremor: tremor, ataxia, weakness, overall functional status and the future need for MRI all have to be assessed separately.
This page focuses specifically on the uncommon situation of DBS for tremor associated with multiple sclerosis, rather than standard indications for deep brain stimulation in Parkinson's disease or essential tremor.
In multiple sclerosis, severe tremor usually results from damage to cerebello-thalamo-cortical networks and often does not occur in isolation.
It is commonly postural and kinetic, including an intention component, and may worsen markedly as the hand approaches a target.
Even if DBS reduces tremor, impaired movement accuracy may persist and limit the real improvement in hand function.
Weakness, spasticity, sensory impairment, poor balance and cognitive problems can all influence the patient's final level of independence.
Deep brain stimulation is not considered an early treatment. It is a potential option for severe tremor that markedly limits daily life and remains refractory to less invasive approaches.
The evidence base is substantially smaller than for essential tremor. Most studies are small, outcome measures differ, and patients vary greatly in MS severity, ataxia and the targets used.
In a 2021 meta-analysis of 17 studies including 168 patients, some improvement in tremor after DBS was reported in approximately 73%.
In the largest retrospective series of 104 patients, clinical and functional improvement at 3 months was observed in 64%.
In the 2025 Mayo Clinic series, the median Fahn–Tolosa–Marin score decreased from 14.5 to 10 at the last follow-up.
In the study by Chagot and colleagues published in 2023, 104 patients with disabling medication-refractory upper-limb tremor were analyzed. At three months, 64% had clinical and functional improvement.
Among responders, 93% maintained a good response at one year. Mean follow-up in this cohort was approximately six years.
In a retrospective series of 18 patients, DBS significantly reduced tremor severity, while overall EDSS did not change significantly. This illustrates an important distinction: reducing tremor is not the same as treating overall disability in MS.
No clinical relapses were recorded after surgery in this series, and among eight patients who had follow-up MRI, no new lesions were seen. These findings are reassuring, but they do not prove absolute safety for every person with MS.
It does not mean that normal hand function is restored in 73% of patients. The meta-analysis combined different scales, targets, follow-up periods and definitions of response. In addition, ataxia and other MS symptoms may persist even when tremor is substantially reduced.
In MS, the success of surgery depends not only on implantation technique. The quality of patient selection may matter more than the choice between closely related anatomical targets.
The ventral intermediate nucleus of the thalamus remains the best studied and most frequently used target for tremor.
A more anterior thalamic region has been studied for complex MS tremor. A 2022 connectomic analysis linked good response to the area around the VOP–VIM border.
The dentato-rubro-thalamic tract is a cerebello-thalamic pathway increasingly used as a reference in tractography-based planning. Its role remains evolving rather than fully standardized.
Dual VIM + VOP leads were previously studied as a way of covering a more complex network. However, in the 2025 Mayo Clinic series, optimal programming in patients with additional targets ultimately used VIM. A more complex lead configuration therefore should not automatically be considered more effective.
The modern concept is not simply to hit an anatomical nucleus, but to modulate the appropriate network. This may be particularly relevant in MS because demyelinating lesions can individually alter connections between the cerebellum, thalamus and motor cortex.
For a person with multiple sclerosis, continued access to repeated MRI of both the brain and spinal cord is especially important. Selection of a DBS system should therefore account not only for the neurosurgical task but also for long-term neuroimmunological monitoring.
MRI is possible with many contemporary systems, but only under device-specific conditions: the exact system model, lead configuration, magnetic-field strength, sequence parameters and placing the system into a dedicated MRI mode.
It is important to understand in advance whether not only brain MRI, but also cervical or thoracic spinal MRI can be performed if needed, since spinal imaging is often required in MS.
Hemorrhage, infection, wound complications and problems with the lead or pulse generator. These are general DBS risks rather than MS-specific complications.
Dysarthria, paresthesias, worsening balance or increased ataxia. Many such effects are reversible after changing stimulation parameters.
Tremor may improve while the expected daily-life function does not, because weakness, ataxia or progression of other MS symptoms remains limiting.
Current literature does not show a convincing signal that stimulation itself provokes inflammatory MS activity. In the 2025 Mayo Clinic series, no clinical relapses were observed after DBS in 18 patients, and no new lesions were seen in patients with available follow-up MRI.
These observations should not be interpreted as proof of zero risk for every patient: sample sizes remain small, and inflammatory MS activity should be monitored independently of DBS.
MR-guided focused ultrasound creates a small thermal lesion in a selected thalamic region without implanting electrodes. It is an attractive technology, but the amount of clinical evidence specifically in MS remains much smaller.
| Feature | DBS | MRgFUS |
|---|---|---|
| Principle | Electrical modulation of a neural network. | Irreversible focal thermal ablation. |
| Adjustment after the procedure | Parameters can be changed and stimulation can be switched off. | The created lesion cannot be adjusted after treatment. |
| Implanted device | Yes. | No. |
| Experience specifically in MS | Patient series, systematic reviews and long-term follow-up are available. | Published evidence is limited to a small number of cases and pilot studies. |
| Main feature | The effect can be programmed and adapted over time. | No implanted hardware is needed, but the effect is produced by an irreversible lesion. |
Tremor, ataxia, weakness, sensory impairment, or a combination of several mechanisms.
Relapses, MRI activity, current disease-modifying therapy and progression that may influence long-term outcome should be assessed.
Medication, botulinum toxin, rehabilitation, occupational therapy and assistive devices.
One or more specific everyday functions should be defined in advance, rather than focusing only on a lower tremor score.
In severe tremor associated with multiple sclerosis, the structure of the movement disorder, MS activity and stage, previous treatment results and the possible role of DBS can be reviewed before discussion with a functional neurosurgery center.
The aim of this consultation is not to “prescribe surgery”, but to determine whether neurosurgical reduction of tremor is likely to provide meaningful functional benefit for this particular patient.
Material updated September 2026. DBS for multiple sclerosis-associated tremor remains an uncommon and individually considered form of functional neurosurgery.